OXITRAN

Welcome to the Brand page for “OXITRAN”, which is offered here for Chemical preparations for the treatment of neuromuscular and ophthalmological diseases; pharmaceutical preparations for the treatment of central nervous system-related conditions, neurological and muscular diseases, neuro-muscular diseases, muscular dystrophies, ataxias, amyotrophia, atrophy, ophthalmological diseases; muscle wasting, cardiomyopathies, optic nerve degradation, neurological indications, memory loss, lou gehrig's disease, parkinson's disease, huntington's disease, spinal muscular atrophies, polyneuropathies, fibromyalgia, mononeuropathies, neuromuscular junction disorders, myotonia and myopathies; reagents for medical use in connection with the aforementioned diseases;active chemical ingredients for use in the manufacture of small molecule pharmaceuticals for treating neuromuscular and ophthalmological diseases; reagents for scientific and medical research for use in the research of small molecule pharmaceuticals and research of the treatment of neuromuscular and ophthalmological diseases; all of the foregoing excluding cleaning agents for use in laboratories and industries;medical research; science research; medical and scientific research, conducting clinical trials; computer programming for others for medical and science research purposes; scientific research for testing cell cultures and developing cellular test systems for evaluating new drugs and antibodies; developing test systems for detecting pharmacologically active compounds; animal model testing and research for neuro-muscular and ophthalmological diseases;.

Its status is currently believed to be active. Its class is unavailable. “OXITRAN” is believed to be currently owned by “Santhera Pharmaceuticals (Schweiz) AG”.